FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Anticoagulation in obese patients: challenges and strategies
1827PDF: 261HTML: 195XML: 77 -
CO29 | Emergency room physicians and oral anticoagulants related bleeding D. Barcellona1,2, G. Melis1, A. Bussu1, M. Orrù1, Ml. Caddeo1, E. Antonucci2, A. Mameli1, F. Marongiu1,2 | 1SSD Emostasi e Trombosi, AOU Cagliari; 2Fondazione Arianna, Bologna, Italy
523PDF: 0 -
PO61 | RISK FACTORS FOR INTRACRANIAL HEMORRHAGE: AN UMBRELLA REVIEW TO INFORM MACHINE LEARNING PREDICTION MODELS IN GLIOMA PATIENTS RECEIVING ANTICOAGULATION T.A. Adeyemo, S. Greenley, F. Ware, W. Jones, A. Maraveyas, F. Haque | 1Centre of Excellence for Data Science, Artificial Intelligence and Modelling DAIM, Faculty of Science and Engineering, University of Hull, UK; 2Hull York Medical School, Hull, UK; 3Academic Library Services, University of Hull, UK; 4NHS Humber Health Partnership, Hull, UK
3PDF: 0 -
CO08 | The utility of urine qualitative assessment for direct oral anticoagulants in routine clinical practice F. Schieppati1,2, P. Gomez-Rosas1,3, C. Ambaglio1, V. Brusegan1, Oc. Cretu1,2, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4,5, A. Falanga1,2, M. Marchetti1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Germany; 5Germany DOASENSE GmbH, Heidelberg, Germany
587PDF: 0 -
Bleeding complications of oral anticoagulant therapy: from ISCOAT to the START Register A memory of Gualtiero Palareti
33PDF: 15 -
PO28 | CLINICAL IMPLICATIONS OF ANTICOAGULANT DRUG INTERACTIONS WITH TARGETED AND IMMUNE THERAPIES IN ONCOLOGY: A CONTEMPORARY RISK STRATIFICATION FRAMEWORK D. Dhami1, C. Solowiej Singh 1, M. Dhami 2 | 1Abrazo Internal Medicine Residency; 2Eastern Connecticut Hematology Oncology, Norwich, CT, USA
1PDF: 0 -
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
4PDF: 1 -
PO31 | Comparative analysis of anticoagulant therapy in patients over 90 years old: vitamin K antagonists versus direct oral anticoagulants G. Sottilotta1, P. Arrigo2, S. Cuzzocrea1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie, Emostasi e Trombosi, Grande Ospedale Metropolitano di Reggio Calabria; 2Associazione Italiana Pazienti Anticoagulati, Sezione di Reggio Calabria; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
446PDF: 0 -
PO83 | A case of deep vein thrombosis in a patient with systemic mastocytosis M. Leotta, A. Ierardi, A. Strangio, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU R Dulbecco, Catanzaro
592PDF: 0 -
PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER S. Guglielmo1, M. Lovisotto1, L. Scarano1, E. De Bon2, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy
1PDF: 0 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
485PDF: 0 -
PO81 | Direct oral anticoagulants in atypical site vein thrombosis: a single centre experience focused on cancer patients U. Mazzarelli1, A. Guida1, L. Agrelli1, M. Amato1, R. Guarrasi2, L. Santaniello2, C. Cardamone1, P. Vitale1, M. Triggiani1 | 1Centro per le Malattie Emorragiche Congenite e Malattie Trombotiche UOC Clinica Immunologica e Reumatologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno; 2UOC Clinica Oncologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
504PDF: 0 -
PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, D. Menichelli1, T. Brogi2, S. Marucci2, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
489PDF: 0 -
CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience A. Hoxha1, E. Campello1, F. Ahmad2, L. Spiezia1, P. Scarinzi1, G. Gobbo1, S. Gavasso1, F. Sartorello1, C. Simion1, E. Zanon1, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED; 2Department of Statistical Sciences) University of Padova, Italy
603PDF: 0 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
1PDF: 1 -
PO53 | Effectiveness and safety of DOACS in patients with renal transplantation A. Ierardi, A. Strangio, M. Leotta, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU Renato Dulbecco, Catanzaro, Italy
467PDF: 0 -
PO77 | The clinical awareness of mixing test interpretation in the era of complex reporting algorithm: do we forget the origins? A. Fassina, L. De Valentin, S. Luzi, R. Turrini, A. Antico, L. Zardo | Laboratorio Analisi Castelfranco Veneto, ULSS Marca Trevigiana, Italy
495PDF: 0 -
OC06 | PRIMARY THROMBOPROPHYLAXIS IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SYSTEMIC ANTICANCER TREATMENT: A CANCER-CENTER COHORT STUDY ON CLINICAL PRACTICE AND OUTCOMES F. Haque1|2, A. Adekeye1|2, Z. Mohtashim2, K. Page1, M. Goodman1, A. Maraveyas 1|2 | 1Hull University Teaching Hospital NHS Trust, UK; 2Hull York Medical School, UK
6PDF: 1 -
CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma; 4IRCCS Neuromed, Pozzilli, Italy
606PDF: 0 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
484PDF: 0 -
PO93 | Use of DOACS in heart transplantation recipients T. Marrazzo1, A. Delle Femine1, C. Amarelli2, R. Albisinni3 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 2UOSD CCH dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 3UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
551PDF: 0 -
PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS S. Ramdani1, C. Séguin2 | 1Division of Hematology, Post-Graduate Medical Education Program, McGill University, Montreal; 2Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada
1PDF: 1 -
PO57 | Direct oral anticoagulant determination in urine samples compared to plasma concentrations in outpatients with atrial fibrillation and obesity A. Pannunzio1, I.M. Palumbo1, D. Menichelli1, V. Cammisotto2, V. Castellani3, E. Baldacci4, R. Mormile4, A. Chistolini4, G. Bernardini5, N. Porcu1, D. Pastori2, J. Harenberg6, F. Violi2, P. Pignatelli2 | 1Department of General Surgery, Surgical Specialties and Organ Transplantation Paride Stefanini, Sapienza University of Roma, Italy; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy; 3Department of Translational and Precision Medicine, Sapienza University of Roma, Italy; 4Department of Hematology, Oncology and Dermatology, Sapienza University of Roma, Italy; 5U.O.S.D. Medicina Rigenerativa DAI, Medicina Diagnostica e Radiologia, Policlinico Umberto 1, Roma, Italy; 6Ruprecht Karls University of Heidelberg, Germany
405PDF: 0 -
PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT S. Kozhukhov, N. Dovganych | SI “NSC “The M. D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; 2Cardio-Oncology Center, Kyiv, Ukraine
1PDF: 0 -
PO89 | Apixaban for secondary prevention of venous thromboembolism in hemodialysis patients: pharmacokinetic profile and safety outcomes S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padua, Italy
586PDF: 0 -
PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati1|2, P. Gomez-Rosas1|3, C. Ambaglio1, V. Brusegan1, O.C. Cretu1, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4|5, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Heidelberg, Germany; 5DOASENSE GmbH, Heidelberg, Germany
2PDF: 0 -
PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK
1PDF: 0 -
PO72 | Fondaparinux in patient with active tuberculosis T. Marrazzo1, R. Parrella2, A. Botta2, A. Pontarelli2, M.P. Ursi3, A. Karruli4, R. Albisinni5 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi, Napoli, Italy; 2UOC Malattie Infettive ad Indirizzo Respiratorio, Ospedale Cotugno Azienda dei Colli, Napoli, Italy; 3UOC MECAU Ospedale CTO Azienda dei Colli, Napoli, Italy; 4Malattie Infettive e Tropicali, Ospedale di Tirana, Albania; 5UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
474PDF: 0 -
OC03 | THROMBOEMBOLIC PREVALENCE IN MULTIPLE MYELOMA BEFORE AND AFTER THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS: A LONGITUDINAL COHORT STUDY A. Ramírez1, A. Orozco2, A. Sánchez3, F. Villalpa1, S. Burgos2, G. Cesarman3, G. Rodríguez1, D. Vieyra2, J. Álvarez4, G.M. Flores3, S. González1, D. Martínez2, B. Cabello3, R. Espinoza3, O. Fernández3 | 1Myeloma-clinic Hematology service, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México City, México; 2Myeloma-clinic Hematology service, Instituto Nacional de Nutrición Salvador Zubirán, México City, México; 3Myeloma-clinic Hematology service, Instituto Nacional de Cancerologçia, México City, Mexico; 4Centro Médico Nacional 20 de Noviembre, México City, Mexico
3PDF: 0 -
PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM I. Mahé1|4, F. Happe2, M. Monreal5|7, H. Robert-Ebadi8, P. Debourdeau9, J. R. Fabreguettes10, S. Accassat11, P. Mismetti4|11|12, P. Girard13, S. Laporte4|12|14, C. Chapelle14 | 1Paris Cité University; 2Assistance Publique - Hôpitaux de Paris, Louis Mourier Hospital, Department of Internal Medicine; 3Inserm UMR-S970, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France; 4F-CRIN INNOVTE Network, France; 5Department of Internal Medicine, Institut de Recerca Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 6Department of Medicine, Universitat Autonoma de Barcelona, Barcelona; 7Universidad Catolica San Antonio de Murcia, Murcia, Spain; 8Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; 9Arles Hospital, Oncology unit, Arles, France; 10Assistance Publique - Hôpitaux de Paris, AGEPS, France; 11Service de Médecine Vasculaire et Therapeutique, CHU de Saint-Etienne, Saint-Etienne, France; 12Université Jean Monnet, Mines Saint-Étienne, INSERM Unité 1059, Santé Ingénierie Biologie Saint-Étienne SAINBIOSE, Saint-Étienne, France; 13Département de Pneumologie, Institut Mutualiste Montsouris, Paris; 14Service de Pharmacologie Clinique, CHU de Saint-Etienne, Saint-Etienne, France
2PDF: 0 -
PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy
490PDF: 0 -
CO05 | Long-term management of upper extremity catheter-related thrombosis in female patients with cancer: a retrospective cohort study Chiara Cavallaro1,2, Paolo Santini1,2, Laura Leoni3, Carolina Mosoni1,2, Silvia D’Ambrosio1,2, Francesco Mancinetti1,2, Nicola Coletta1,2, Michela Iorio1,2, Angelo Porfidia1,2, Alessandro D’Errico1,2, Rosa Talerico1,2, Roberto Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Università Cattolica del Sacro Cuore, Rome; 3Vita-Salute University, San Raffaele Hospital IRCCS, Milan, Italy
519PDF: 0 -
PO31 | MIGRATORY SUPERFICIAL THROMBOPHLEBITIS REFRACTORY TO APIXABAN IN A PATIENT WITH LUNG ADENOCARCINOMA I. Goldberg1|2, P. Raanani1|2|3, G. Spectre1|2 | 1Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel; 2Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; 3Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel
1PDF: 0 -
PO18 | Does muscle mass matter? Appendicular lean mass as a determinant of anti-XA activity in elderly patientes B.M. Zanforlini1, V. Bernardi1, E. Campello2, E.M. Bicego1, C. Curreri1, A. Vaticano1, C. Sartori1, L. Manfron1, A. Perencin1, P. Rollo1, A. Baruffol1, L. Ruoso1, C. Simion2, C. Bulato2, P. Berto2, P. Simioni2, G. Sergi1 | 1Department of Medicine, Geriatrics Section, University of Padova; 2Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine DIMED, Padova University Hospital, Padova, Italy
484PDF: 0 -
PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas1|4, Y. Mitrou5, M. Marchetti6, P. Las Casa1, A. Tafur7, V. Bitsadze3, J. Khizroeva3, D. Taizhanova8, D. Antic9, C. Frére10, A. Makatsariya3, L. Garderet1|11, A. Escargueil1, C. Ay12, N. Lomatkin13, Z. Tazi-Mezalek14, M. Sassi15, M. Catalano4|16, J. Gligorov1|17, J. Caprini18, P. Van Dreden1|19, J. Fareed2, A. Falanga6 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; 2Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 3Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; 5Department of Phylosophy, National and Kapodistrian University of Athens, Greece; 6Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 7Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; 8Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; 9Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; 10Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; 11Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; 12Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; 13Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; 14Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; 15Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; 16Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; 17Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 18Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; 19Clinical Research, Diagnostica Stago, Gennevilliers, France
1PDF: 0 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
1PDF: 0
1 - 55 of 55 items
